<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473316</url>
  </required_header>
  <id_info>
    <org_study_id>GP27913</org_study_id>
    <nct_id>NCT01473316</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980</brief_title>
  <official_title>An Open-Label, Fixed-Sequence, 2-Period Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This will be an open-label, fixed-sequence, single-center, 2 period study. The study is
      designed to determine the effect of ketoconazole on the pharmacokinetics of GDC-0980.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: maximum observed plasma concentration</measure>
    <time_frame>Up to approximately 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: time to reach maximum observed plasma concentration</measure>
    <time_frame>Up to approximately 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to approximately 40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory test results (hematology and serum chemistry)</measure>
    <time_frame>Up to approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign measurements (sitting systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature)</measure>
    <time_frame>Up to approximately 8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Repeating Oral Dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal and/or surgically sterile adult nonsmoking female subject
             between 18 and 65 years of age, inclusive, with a body mass index of 18 to 32 kg/m2,
             inclusive

          -  Medically healthy as determined by the absence of clinically significant findings in
             the physical examination, medical history, vital sign measurements, clinical
             laboratory tests, or 12 lead electrocardiograms (ECGs) as determined by the
             investigator

          -  Female subject of nonchildbearing potential

        Exclusion Criteria:

          -  History or clinical manifestations of significant metabolic (including type 1 and 2
             diabetes), hepatic, renal, hematological (including hypercholesterolemia and
             triglyceridemia), pulmonary, cardiovascular, endocrine, gastrointestinal (including
             gastric or duodenal ulcers), urological, neurological, or psychiatric disorders, or
             cancer

          -  History of inflammatory arthritis

          -  History of symptomatic hypotension

          -  History of severe physical injury, direct impact trauma, or neurological trauma within
             6 months before Day 1 of Period 1

          -  History of seizure disorders

          -  History of bipolar or major depressive disorder

          -  History of stomach or intestinal surgery or resection that could potentially alter
             absorption and/or excretion of orally administered drugs, with the exception of
             appendectomy, hernia repair, and cholecystectomy, which are allowed

          -  History of active liver disease, including hepatitis or cirrhosis

          -  History or presence of an abnormal ECG

          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias

          -  Abnormality on the chest x-ray at Screening determined to be clinically significant by
             the investigator and medical monitor

          -  History of alcoholism, drug abuse, or drug addiction

          -  Used any nicotine-containing or nicotine-replacement products within 6 months before
             Day 1 of Period 1

          -  Participated in any other investigational drug study in which receipt of an
             investigational study drug occurred within 1 month or 5 half-lives before Day 1 of
             Period 1

          -  Used any prescription medications/products including monoamine oxidase inhibitors,
             thioridazine, pimozide, or antidepressants within 1 month (2 weeks for antibiotics)
             before Day 1 of Period 1, with the exception of hormone replacement therapy or 2
             weeks' use of narcotics for pain, unless deemed acceptable by the investigator

          -  Used medications capable of inhibiting hepatic enzymes within 1 month or 5 half-lives
             before Day 1 of Period 1

          -  Received any vaccination or immunization within 1 month before Day 1 of Period 1

          -  Used proton pump inhibitors or histamine H2 receptor antagonists within 1 month before
             Day 1 of Period 1

          -  Known hypersensitivity to ketoconazole, or other azole antifungals

          -  Used any over-the-counter, nonprescription preparations within 7 days before Day 1 of
             Period 1, unless deemed acceptable by the investigator

          -  Used alcohol-containing, grapefruit-containing, or caffeine containing foods or
             beverages within 72 hours before Day 1 of Period 1, unless deemed acceptable by the
             investigator

          -  Poor peripheral venous access

          -  Donated blood within 2 weeks or plasma within 1 week before Day 1 of Period 1

          -  Received blood products within 2 months before Day 1 of Period 1

          -  Positive urine drug or alcohol screen

          -  Positive screen for hepatitis B surface antigen, hepatitis C virus, or human
             immunodeficiency virus types 1 and 2

          -  Diagnosed with a vitamin B12 deficiency

          -  Any acute or chronic condition that, in the opinion of the investigator, would limit
             the subject's ability to complete or participate in this clinical study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

